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Abstract: Papillary renal cell carcinoma (pRCC) is a malignant kidney cancer with a prevalence of 
7–20% of all renal tumors. Proteome and metabolome profiles of 19 pRCC and patient-matched 
healthy kidney controls were used to elucidate the regulation of metabolic pathways and the 
underlying molecular mechanisms. Glutathione (GSH), a main reactive oxygen species (ROS) 
scavenger, was highly increased and can be regarded as a new hallmark in this malignancy. 
Isotope tracing of pRCC derived cell lines revealed an increased de novo synthesis rate of GSH, 
based on glutamine consumption. Furthermore, profound downregulation of gluconeogenesis and 
oxidative phosphorylation was observed at the protein level. In contrast, analysis of the The 
Cancer Genome Atlas (TCGA) papillary RCC cohort revealed no significant change in transcripts 
encoding oxidative phosphorylation compared to normal kidney tissue, highlighting the 
importance of proteomic profiling. The molecular characteristics of pRCC are increased GSH 
synthesis to cope with ROS stress, deficient anabolic glucose synthesis, and compromised 
oxidative phosphorylation, which could potentially be exploited in innovative anti-cancer 
strategies. 
Keywords: Papillary renal cell carcinoma (pRCC); proteome profiling; metabolome profiling; 
glutathione metabolism; metabolic reprogramming 
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1. Introduction 
Papillary renal cell carcinoma (pRCC) is a heterogeneous disease, representing 7–20% of all 
renal cancers [1–3], subdivided into clinically and biologically distinct type I and type II entities [3]. 
Type I pRCC tumors consist of basophilic cells with papillae and tubular structures and small 
nucleoli, whereas pRCC type II tumors exhibit large cells with abundant eosinophilic cells and 
prominent nucleoli [3]. The cytogenetic differences are a trisomy 7 and 17 in pRCC type I and the 
loss of 1p and 3p in pRCC type II tumors [4,5]. Intra- and interchromosomal rearrangements are 
significantly increased in pRCC type II, leading frequently to a gene fusion involving the 
transcription factor TFE3 [6], by which the promoter substitution appears to be the key molecular 
event, causing dysregulation of many signaling pathways already implicated in carcinogenesis [7]. 
Type I of this malignant tumor is characterized by frequent mutations in the MET oncogene, 
including alternative splice variants. Currently, the MET pathway is the most common target for 
developing new treatments for pRCC, such as the MET kinase inhibitor Savolitinib, which 
interrupts angiogenesis [8]. Type II has more likely mutations such as SETD2, NF2, and the 
inactivation of CDKN2A by mutation, deletion, or CpG island hypermethylation [5,9]. Structural 
variants were observed in sporadic events, including duplications in EGFR and HIF1A, and 
deletions in SDHB, DNMT3A, and STAG2 [10]. These genes and several more, which can be found 
mutated in both tumor types, play a pivotal role in epigenetic regulation, signaling, and 
proliferation regulation, such as in PI3K/AKT/mTOR, NRF2-ARE, and the Hippo pathways. 
Furthermore, type II pRCC was subdivided into three subtypes, based on distinct molecular and 
phenotypic features. pRCC type II tumors are more likely to metastasize [4], and FH mutations and 
DNA hypermethylation were found to be correlate with inferior prognosis [5,9]. Hence, the 
hypermethylation group was termed “CpG island methylation phenotype” (CIMP), which 
additionally featured a metabolic shift known as the Warburg effect [5].  
Many studies have been performed recently at the transcript level in pRCC to better 
understand its classification and subclassification and to elucidate pathway remodeling in these 
cancer [5,11] studies. Based on all these findings, a new classification system was proposed. 
Compared with the current model where the organ of origin determines the tumor type, a system 
was proposed based solely on molecular features which could be considered more relevant for 
tumor classification [12].  
Nephrectomy or partial nephrectomy and in the presence of metastases, and treatment with 
vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors 
are currently considered the standard treatments. Furthermore, resection or irradiation of 
metastases can be a useful palliative treatment for patients with brain metastases or osseous 
metastases that are painful or increase the risk of fracture [13]. 
Besides transcript data, little is known in pRCC about its regulation at the protein- and 
metabolome level, the underlying molecular mechanisms, the alterations of metabolic pathways, 
and how well these “omics” data correlate with each other. One study compared 
metabolomic/lipidomic profiles of clear cell RCC (ccRCC), chromophobe RCC (chRCC), and pRCC, 
and determined that RCC subtypes clustered into two groups separating ccRCC and pRCC from 
chRCC, which mainly reflected the different cells of origin [14].  
To fill in the aforesaid knowledge gaps, we undertook a multi-‘omics’ survey to compare seven 
type I, seven type II, and five metastatic type II pRCCs with patient-matched adjacent healthy 
kidney tissues. To confirm the main findings obtained by profiling, the dysregulated pathways 
were validated by either enzymatic measurements or isotope tracing experiments. 
2. Results 
2.1. Proteome Profiling of pRCC 
Malignant and non-malignant tissues from 19 nephrectomies representing papillary RCC of 
type I, II, and IIM (with metastases) were investigated; clinical parameters are shown in Table 1. 
Proteome profiling revealed a total of 8554 protein groups, consisting of 1,330,129 identified 
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peptides in all 19 pRCC samples and adjacent healthy kidney tissues, both at a false discovery rate 
(FDR) of 1% (Table S1). 3785, 3838, and 4200 protein groups could be quantified by label-free 
quantification in type I, II, and IIM, respectively.  
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Pearson correlation ranged from 0.597 to 0.951 for controls and 0.631 to 0.938 for all pRCC 
specimens for the least to the most similar individuals. Furthermore, proteome profiling revealed 
pRCC I, II, and IIM versus healthy adjacent kidney tissues as distinct groups in a principal 
component analysis (Figures 1A–C).  
 
Figure 1. Principal component analysis (PCA) and evaluation of the mitochondrial DNA (mtDNA) 
and mitochondrial protein content in papillary renal cell carcinoma (pRCC). PCA analysis in (A) 
pRCC type I (n = 6), (B) pRCC type II (n = 6), and (C) pRCC type IIM (n = 4) revealed spatial 
separation for the proteome profiles. (D) Log2 ratios of the mtDNA (mean −0.55 ± 1.7 standard 
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deviation (SD) based on whole-exome sequencing (WES) read depths, the mitochondrial- (mean 
−0.19 ± 1.13 SD) and non-mitochondrial proteome (−0.22 ± 0.86 SD) in pRCC versus controls, (n = 
19). 
Significantly regulated proteins were identified by a t-test and volcano plots are shown for 
pRCC type I, II, and IIM (Table S2, Figures S1A–C). 
2.2. mtDNA Mutations in pRCC Did Not Reveal any Major Impact on the Respiratory Chain  
The assembly of mitochondrial whole-exome sequencing (WES) reads derived from 19 patients 
with pRCC and matched with adjacent healthy kidney tissues showed adequate coverage and 
quality for reliable mtDNA reconstruction and variant calling (Table S3). Mitochondrial mean 
coverage read depth and mitochondrial assembled bases in the WES dataset ranged from 12.42X to 
371.41X and from 91.21% to 100%, respectively. The mtDNA content was 46% reduced (Figure 1D), 
based on log2 ratios of the mtDNA WES read depths between pRCC and matching controls, which 
is in line with a previous observation in RCC by Southern blot [15]. Furthermore, the abundance of 
proteins located within the mitochondrion versus all non-mitochondrial proteins showed no 
difference (Figure 1D).  
A total of 260 somatic mtDNA mutations were detected in pRCC samples. Altogether 86 
mutations were located within the protein-coding genes, divided into 44 synonymous, 40 non-
synonymous and two nonsense mutations. Among the non-synonymous variants, 25 showed a 
disease score higher than the threshold (>0.7) and a nucleotide variability that was lower than the 
nucleotide variability cutoff (0.0026). A total of 197 germline mutations were detected, but only one 
of the seven non-synonymous germline variants were shown to be potentially pathogenic (Table S4).  
Although 25 somatic non-synonymous and potentially pathogenic events were identified, it 
was not possible to infer a strong relationship with pRCC, considering that all mutations were 
found in only ten of the 19 tumors. None of the somatic mutations were shared between the 
different subjects and homoplasmic rates were generally very low (Table S4), however, the number 
of studied cases was too low to draw any final conclusions.  
An analysis of copy number variations (CNV) revealed a fragmented pattern of chromosomal 
gains and losses spread over all chromosomes in all pRCC types (Figure S2), but no clear 
chromosomal patterns were identified. 
2.3. Significantly Decreased Enzymatic Activity of the Respiratory Chain in pRCC 
A gene set enrichment analysis (GSEA) was conducted to identify significantly rewired 
metabolic pathways in the tumor. Significant decreases in all three investigated pRCC types were 
found in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for oxidative 
phosphorylation, thetricarboxylic acid cycle (TCA), branched-chain amino acids, cytochrome P450 
drug metabolism, peroxisomes, fatty acid metabolism, and several amino acid metabolism 
pathways. (Figure 2A, Figure S3, Table S5). The OXPHOS system was the most severely reduced in 
all pRCC types. Interestingly, there was no obviously different regulation between the three types 
of pRCC that was detectable at the protein pathway level. The three most significantly increased 
KEGG pathways in all pRCCs were the spliceosome, the ribosome and the cell cycle (Figure 2A; 
Figure S3, Table S5). An aberrantly increased rate of ribosome biogenesis has been recognized as 
a hallmark of many cancers, caused by hyperactivation of RNA polymerase I transcription and 
ribosome biogenesis factors, reviewed in [16,17].  
In order to investigate the regulation of the respiratory chain between pRCC and controls in 
more detail, separate gene sets for all five OXPHOS complexes were created, including the 
assembly factors. This revealed a reduction in protein abundance for all complexes with the highest 
observed for complex I (CI) in pRCC, exemplarily shown for type I tumors (Figure 3A, Figure S4). 
Only assembly factors, that weren’t part of the final complexes, were not decreased.  
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Figure 2. Significantly regulated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
between the proteomes of (A) papillary renal cell carcinoma (pRCC) type I and healthy kidneys and 
(B) of the transcriptome data retrieved from The Cancer Genome Atlas (TCGA). Shown is a 
collapsed list, the applied cutoff is p  ≤  0.05 and q ≤  0.1. Specific enrichment plots for the KEGG 
pathway “oxidative phosphorylation” are shown for (C) the proteome and (D) the transcript data 
from TCGA. The Vacuolar-type H ± ATPases (V-ATPases) were removed from the pathway 
“oxidative phosphorylation” displayed in C and D, as they are wrongly assigned in this KEGG 
pathway. Normalized enrichment score, NES; Size, number of proteins/genes identified within a 
pathway. 
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Figure 3. Protein abundance ratios for all individual complexes of the respiratory chain, shown for 
(A) papillary renal cell carcinoma (pRCC) type I and (B) renal oncocytomas. Illustrated are schemes 
of the four OXPHOS complexes and the F0F1ATPase, including subunits and assembly factors and 
the according log2 fold change between pRCC or renal oncocytomas versus kidney samples. The 
color gradient intensity in the subunit expresses the low (blue) or high (red) abundance of this 
protein in the tumor. Assembly factors, not part of the final complexes are shown in bold. * indicates 
significantly regulated proteins. 
2.4. Anti-correlation of Transcripts and Proteins of the Respiratory Chain in pRCC  
Altogether, 291 existing pRCC and 32 control transcriptome data retrieved from TCGA (ID: 
KIRP) [5] were used to clarify the correlation between the abundance of proteins and the expression 
of transcripts in pRCC versus controls (Table S6). GSEA was performed and identified that most of 
the significantly regulated pathways (Figure 2B, Figure S3, Table S7) were very similarly regulated 
for our proteome study. The ribosome and cell cycle were significantly increased in both omics 
datasets, whereas the TCA cycle, drug metabolism, fatty acid metabolism, and the pathways 
involved in amino acid metabolism were all significantly decreased (Figures 2A,B; Figures S3A,B, 
Table S5, and S7). The only striking differences were the “spliceosome” pathway, which was 
significantly up-regulated only in the pRCC proteomes and the “oxidative phosphorylation” 
pathway, which was the most decreased pathway at the protein level (Figure 2C, Figures S3C,D), 
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but that was unchanged at the transcript level (Figure 2D). Since this KEGG pathway also includes 
the vacuolar-type H ± ATPases (V-ATPases), which are not part of the respiratory chain, we 
manually removed them from the analysis. The enzymatic activities of the individual respiratory 
chain complexes and citrate synthase (CS) were measured for pRCC and the adjacent matching 
healthy tissues. This revealed a significant reduction in all enzymatic activities of the respiratory 
chain, the F0F1 ATPase, and CS in pRCC (Figure 4A–F). Thus, the regulation of the respiratory chain 
was not determined by the abundance of the respective transcripts but was correlated with the 
abundance and enzymatic activity of the OXPHOS complexes.  
 
Figure 4. Enzymatic activities of the respiratory chain, F0F1 ATPases, citrate synthase, and the P- and 
V- ATPases in papillary renal cell carcinoma (pRCC) versus kidney control tissues. (A) Complex I 
(CI), (B) Complex II (CII), (C) Complex III (CIII), (D) Complex IV (CIV), (E) F0F1 ATPase (CV), (F) 
Citrate synthase (CS), (G) P-ATPases, (H) V-ATPases. P-values are: * p < 0.05, ** p < 0.01, and *** p < 
0.001 by a paired t-test; nmol min/mg protein. n = 3 for each type I, II, and IIM.  
2.5. Comparison of the Abundance of Proteins Involved in the Respiratory Chain between Malignant pRCC 
and Benign Renal Oncocytomas 
In our previous study on renal oncocytomas, we identified a coordinated up-regulation of 
proteins of the OXPHOS complexes II-V and the mtDNA, but a striking reduction in the abundance 
of CI proteins (Figure 3A) [18]. This was explained by several specific low-level heteroplasmic 
mtDNA mutations of the CI genes in renal oncocytomas. In contrast, all pRCC tumor types featured 
a general reduction in all OXPHOS complexes (Figure 3B, Figure S4) where mtDNA mutations 
seemed to play no major role, but where the number of mtDNA molecules correlated with 
respiratory chain protein abundances between these tumor entities.  
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2.6. pRCCs have Significantly Decreased Levels of V- and P-ATPases 
Vacuolar-type H+-ATPases (V-ATPase) acidify a wide array of intracellular organelles and 
pump protons via ATP hydrolysis across intracellular and plasma membranes. Acidity is one of the 
main features of tumors, V-ATPases control their microenvironment by proton extrusion into the 
extracellular medium [19]. This allows secreted lysosomal enzymes to work more efficiently to 
degrade the extracellular matrix and promote cellular invasion. In contrast to almost all other 
cancer types, the V-ATPases were found to be down-regulated in pRCC: This specifically applies to 
the V-type proton ATPase subunit B, kidney isoform (ATP6V1B1), 21-, 14-, 13-fold (fold changes are 
shown sequentially for type I, II, IIM, respectively) and others such as ATP6V1H, 3-, 4-, 4-fold; 
ATP6F1, 3-, 3-, 2-fold; ATP6V1E1, 3-, 3-, 4-fold; and ATP6V1A, 2-, 2-, 2-fold; (Table S2). This seems 
to be a specific feature of pRCC and might play a key role in malignancy. 
Similar to the V-ATPases, P-type cation transport ATPases, and the subfamily of Na+/K+ 
ATPases were decreased in pRCC (ATP1A1, 4-, 4-, 5-fold; ATP1B1, 4-, 6-, 5-fold; Table S2). These 
ATPases are an integral part of the membrane proteins responsible for establishing and maintaining 
the electrochemical gradients of Na+ and K+ ions across the plasma membrane. They are also 
important for osmoregulation, sodium-coupled transport of several organic and inorganic 
molecules, and the electrical excitability of nerve and muscle. The enzymatic activities of V- and P- 
ATPase types were evaluated and showed a significantly reduced activity in pRCC tissues (Figure 
4G,H), which correlated to the observed protein abundances. 
2.7. Anabolic Glucose Synthesis was Abated in pRCC 
The KEGG pathway “glycolysis and gluconeogenesis” was significantly reduced in pRCC 
(Table S5). This pathway describes two opposing functions: the metabolic generation of pyruvate 
from glucose and the anabolic synthesis of glucose from different substrates, such as glycerol, 
lactate, pyruvate, propionate, and gluconeogenic amino acids. A more detailed view of each 
metabolic pathway showed that the abundance of all glycolytic enzymes was either unchanged or 
increased, whereas all enzymes solely involved in gluconeogenesis were significantly reduced in 
most pRCCs, such as for pyruvate carboxylase (PC) (17-, 16-, 7-fold), phosphoenolpyruvate 
carboxykinase 1 (PCK1) (124-, 136-, 388-fold), phosphoenolpyruvate carboxykinase 2 (PCK2) (12-, 
11-, 45-fold), fructose-bisphosphate aldolase B (ALDOB)(100-, 208-, 145-fold), fructose-1,6-
bisphosphatase 1 (FBP1) (5-, 12-, 49-fold), and fructose-1,6-bisphosphatase 2 (FBP2) (not detected 
(nd), nd, 53-fold) (Figures 5A-C, Table S2). Interestingly, the two fructose-bisphosphate aldolase 
isoforms A (2-, 2-, 5-fold) and C (1-, 1-, 4-fold) were instead increased or unchanged in pRCC 
(Figure 5D).  
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Figure 5. Protein abundances of gluconeogenic enzymes in papillary renal cell carcinoma (pRCC) 
and normal kidney tissues. (A) PCK1, phosphoenolpyruvate carboxykinase 1; (B) FBP1, fructose-
1,6-bisphosphatase; (C) ALDOA, fructose-bisphosphate aldolase A; (D) and ALDOB. P-value is: *** 
p < 0.001 by a two-tailed Student’s t-test. 
These isoforms have a high affinity for fructose-bisphosphate (FDP) to foster glycolysis, 
whereas the highly diminished isoform B has a low affinity for FDP and hence converts the back-
reaction from glyceraldehyde-3-phosphate to FDP during gluconeogenesis [20,21]. A similar 
decrease in the respective transcripts was found in the TCGA data, where ALDOB was 600-fold and 
ALDOC 2-fold decreased and ALDOA 2-fold increased.  
A specific and regulated interaction between ALDOB and the rate-limiting gluconeogenic 
enzyme fructose-1, 6-bisphosphatase 1 (FBP1) has been shown. This result confirms the view that 
ALDOA and ALDOB play different roles in glucose metabolism [22]. The shut-down of the 
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gluconeogenic pathway was thus one of the most relevant metabolic changes observed and can be 
regarded as a metabolic hallmark in pRCC. 
2.8. Dramatically Increased Glutathione Levels in pRCC are Based on Glutamine Consumption  
Metabolome profiling revealed a highly significant increase in reduced glutathione (GSH, 47-, 
68-, 219-fold; fold changes are shown sequentially for type I, II, IIM, respectively) and oxidized 
glutathione (GSSG, 871-, 847-, 6,707-fold) in pRCC types, Figures 6A-F, Table S8). A case by case 
specific GSH/GSSG ratio was calculated (Figure 6F) and revealed that there was a 10-fold average 
increase in oxidative stress burden in the tumor. 
Glutathione functions as a cellular redox buffer for detoxification and can be either synthesized 
de-novo or imported via the glutathione salvage pathway, where extracellular GSH is cleaved by γ-
glutamyltranspeptidases (GGTs) [23]. Furthermore, ophthalmic acid, a tripeptide analog of 
glutathione, was increased (468-, 77-, 58-fold) in pRCC. It was described as a byproduct of 
glutathione synthetase (GS) and γ-glutamylcysteine synthetase (GCS) and as a new biomarker of 
oxidative stress [24].  
 
Figure 6. Metabolome profiling, specific abundancies of reduced and oxidized glutathione in 
tissues, and de novo synthesis of glutathione in papillary renal cell carcinoma (pRCC) Metabolome 
profile of (A) pRCC type I (n = 6), (B) pRCC type II (n = 6), and (C) pRCC type IIM (n = 4) versus 
kidney tissues. Significantly (FDR < 0.05) up- and down-regulated metabolites are shown in red and 
blue, respectively. (D) Relative abundance of glutathione (GSH) and (E) of oxidized glutathione 
(GSSG) in the tissues and (F) the according case-specific GSH/GSSG ratios. Metabolic tracing of 
(G,H) 13C6 glucose and of (I,J) 13C515N glutamic acid to monitor GSH (G,I) de novo synthesis and its 
oxidation product GSSG (H,J) in the pRCC cell lines Caki-2 and ACHN compared to HK-2 control 
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cells. (K) Proline de novo synthesis based on 13C515N glutamic acid in the same cell lines. Mean ± SD, 
n = 3 cell culture replicates, p-values: * p < 0.05, ** p < 0.01, and *** p < 0.001 by a paired t-test. 
Remarkably, even though metabolites involved in glutathione metabolism were significantly 
increased in pRCC, the abundance of glutathione synthetase (GSS) was unchanged (1-, 1-, 1-fold; Table 
S2). Glutamate cysteine ligase (GCL) is the rate-limiting step in GSH biosynthesis. Only the pRCC 
type IIM had significantly elevated levels of glutamate cysteine ligase regulatory subunit (GCLM) 
(1-, 2-, 10-fold), the regulatory subunit of this enzyme alleviates the feedback inhibition of GSH 
together with the catalytic subunit GCLC [25].  
Cysteineglutathione disulfide, which can react with protein thiol groups, causing the reversible 
post-translational modification S-glutathionylation for transducing oxidant signals [26] was (187-, 
17-, 11-fold) elevated. In contrast, the glutathione S-transferase A2 (GSTA2, 146-, 36-, 85-fold), 
microsomal glutathione S-transferase 1 (MGST1, 5-, 1-, nd-fold), and glutathione S-transferase Mu 2 
and 3 (GSTM2, 5-, 5-, 3-fold; GSTM3, 8-, 10-, 5-fold), which conjugate reduced glutathione to a wide 
number of exogenous and endogenous hydrophobic electrophiles, were reduced in pRCC, but other 
enzymes were unchanged, such as glutathione S-transferase theta-1 (GSTT1), glutathione S-
transferase P (GSTP1), glutathione S-transferase kappa 1 (GSTK1), and glutathione S-transferase 
omega-1 (GSTO1). Glutathione peroxidase 3, which protects cells and enzymes from oxidative 
damage by catalyzing the reduction of hydrogen peroxide, lipid peroxides, and organic 
hydroperoxide was also significantly reduced in pRCC (GPX3, 6-, 5-, 6-fold).  
The two identified glutathione transferases, which catalyze the conjugation of GSH to 
xenobiotic substrates for detoxification, were also strongly reduced in pRCC, e.g., glutathione 
hydrolase 1 proenzyme GGT1 (3-, 4-, 4-fold) and GGT5 (20-, 8-, 17-fold). They cleave the gamma-
glutamyl peptide bond of glutathione conjugates, the only one identified was gamma-glutamyl 
lysine, which was increased (2-, 3-, 3-fold) in pRCC. γ-Glutamyl amino acids can be further 
metabolized by γ-glutamyl cyclotransferase (GGACT) [27], whose level was decreased (13-, 45-, 
108-fold) to produce pyroglutamic acid (5-oxoproline), which was not significantly regulated (2-, 2-, 
-2-fold) as well as other amino acids.  
These data show a notable rewiring of the entire process of glutathione metabolism in pRCC, 
however, metabolite and protein abundances do not necessarily reflect the metabolic flux. To 
address the question, as to whether GSH is continuously made by de novo synthesis and which 
substrates significantly contribute to its synthesis, two isotope tracing experiments were performed 
in the pRCC derived cell lines Caki-2 and ACHN and the kidney control cell line HK-2 at time 
points 0, 12, and 24 hours. The first experiment employed 13C6 labeled glucose, the second 13C515N 
glutamic acid as a tracer, a generalized labeling scheme for both is depicted in Figure 7. 
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Figure 7. Scheme of the de novo synthesis pathway of glutathione. (A) based on 13C6 glucose and (B) 
on 13C515N glutamic acid as tracers. Red circles, 13C6; black circles, 12C6. CBS, cystathionine b-
synthetase; CTH, cystathionase; GCL, glutamate-cysteine ligase; GSS, glutathione synthetase; GPx, 
glutathione peroxidase; GR, glutathione reductase; GSSG, oxidized GSH. Of note, GSSG can exist in 
three versions in parallel, as it is made of two GSH molecules: 13C6, 13C3, and 12C when 13C6 glucose is 
the tracer and 13C1015N2, 13C515N, and 12C14N when 13C515N glutamic acid is the tracer. 
Only a slight increase was observed for the de novo synthesis of GSH and GSSG in Caki-2 cells 
(1-fold-, 2.8-fold at 24 h) and ACHN cells (2.1-fold-, 2.2-fold at 24 h) compared with HK-2 cells 
when 13C6 glucose was used as the probe (Figures 6G,H). In contrast to this, a significant and 
dramatic increase of GSH and GSSG de novo synthesis was observed for both, Caki-2 (48.5-fold-, 
10.8-fold at 24h) and ACHN (11-fold-, 12-fold at 24h) cells, when 13C515N glutamic acid was used as 
a probe (Figures 6I,J). Our data demonstrated that GSH de novo synthesis is significantly increased 
in pRCC cell lines and is based on glutamine consumption, a precursor of glutamate.  
2.9. Glutamine is the Main Nutrient Source in pRCC  
In general, glucose and glutamine are the main carbon sources in eukaryotic cells. Tumor cells 
frequently reduce OXPHOS capacity and are therefore even more dependent on nutrient 
consumption. Proteome profiling showed that the abundance of proteins involved in proline 
synthesis, such as CAD protein (CAD, 2-, 5-, 10-fold), aldehyde dehydrogenase family 18 member 
A1 (ALDH18A1), 1-, 2-, 14-fold; pyrroline-5-carboxylate reductase 1 (PYCR1), nd, nd, 115-fold; and 
PYCR2, 5-, 7-, 15-fold, Table S2) increase from type I over type II leading to the highest values in 
metastatic type IIM, indicating a metabolic shift towards proline de novo synthesis originating from 
glutamine. Based on these results, an isotope tracing experiment was performed in pRCC derived 
cell lines Caki-2 and ACHN versus HK-2 kidney controls to quantify the consumption of 
isotopically labeled glutamate for proline de novo synthesis. 
Tracing of 13C515N glutamic acid revealed a significant and (6.3-, 3.9-fold) increase of 13C515N 
proline after 12 hours in the pRCC derived cell lines Caki-2 and ACHN versus HK-2 (Figure 6K). 
The high flux in pRCC cell lines correlates well with the abundance of protein in pRCC tissues of 
enzymes involved in this pathway showing that these tumor cell lines are dependent on glutamine 
consumption.  
3. Discussion 
pRCCs are well characterized at the genomic level, with several driver mutations and 
chromosomal rearrangements having been identified [5]. How these alterations translate to 
proteome- and metabolome regulation are not well understood, but they determine the fate and 
progression of tumors. Multi-omics profiling of pRCC was performed, revealing a fundamental 
reprogramming of the pathways for gluconeogenesis, the respiratory chain, and for glutathione 
metabolism. These can be regarded as a general hallmark of kidney tumors, as was previously 
observed in renal oncocytomas [18], chRCCs [28], and in ccRCCs at the transcript level [29]. The 
anti-correlations that have been identified between genetic and non-genetic profiling argue for 
focusing on these so far under-studied fields. 
Gluconeogenesis, an anabolic and highly endergonic pathway, generates glucose from small 
carbohydrate precursors, for example from lactate during intense exercise, or over periods of fasting 
and starvation. This pathway is also regarded as an essential process for tumor cell growth [30], since 
biosynthetic reactions in cancer cells are highly dependent on glycolytic intermediates [31]. The 
kidney may be nearly as important as the liver in gluconeogenesis [32] and pRCCs have been 
shown to moderately accumulated glucose, which further increases the already higher Fuhrman 
grades [33]. This might be the reason why pRCCs reduce this endergonic pathway, since enough 
glucose can be imported. Blocking of mTOR activity was shown to augment shuttling of pyruvate 
into gluconeogenesis, which results in futile cycling of glucose that finally leads to a halt in cancer 
cell proliferation and ultimately to cell death [34]. Equal amounts of amino acid levels were 
Cancers 2019, 11, 1298 13 of 22 
detected in pRCC and kidney tissues in our study, supporting the idea of a sufficient nutrient 
supply. 
The gluconeogenic gene FBP1 was previously found to be down-regulated in over 600 ccRCCs 
and was associated with a poor disease prognosis. Thus, FBP1 has been shown to fulfill two distinct 
functions, by antagonizing glycolytic flux and thus inhibiting the Warburg effect, and by inhibiting 
the nuclear function of hypoxia-inducible factor (HIF) in a catalytic-activity-independent manner, 
leading to reduced expression of HIF targets such as VEGF, LDHA, and GLUT1 [29]. This unique 
dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing it from other 
tumor suppressors that are not consistently mutated in all tumors [29].  
Moreover, the inhibition of FBP1 leads to the activation of AMP-activated protein kinase 
(AMPK). The aldolases (A–C) are required for the formation of a super lysosomal complex 
containing V-ATPase, ragulator, axin, liver kinase B1 (LKB1), and AMPK in its active form [35]. 
AMPK activation plays a central role in glucose sensing at the lysosome and acts contrary to other 
regulatory systems such as the mammalian target of rapamycin (mTOR).  
A general shut-down of the entire gluconeogenesis pathway in pRCC was also identified at the 
proteome level in our study, which has fundamental implications for the metabolic regulation of a 
cell and organ. Specifically, the two aldolase isoforms A and C, which foster glycolysis were either 
increased or unchanged, but the aldolase isoform B, necessary for gluconeogenesis was greatly 
diminished in pRCC (Figures 5C,D). Conversely, an increase of the ALDOB enzyme is frequently 
found in other tumor species, such as in colon cancer [36], rectal cancer [37], and colorectal 
adenocarcinoma [38], which was also associated with tumor progression and poor prognosis, and a 
decrease of the ALDOB transcript and ALDOB protein is found in gastric cancer [39] and in chRCC [28], 
also associated with poor prognosis [39]. This indicates a critical metabolic rewiring of 
gluconeogenesis in an organ and tumor-specific way. 
Also the up-regulation of ALDOA has been reported in many cancer types, such as oral 
squamous cell carcinoma [40], hepatocellular carcinoma [41], and in RCC [42] and of ALDOA in 
ccRCC [43], osteosarcoma [44], and lung cancer [45]. Specifically, an increase in ALDOA was shown 
for all RCC types and was associated with metastasis, histological differentiation, and poor 
prognosis. Furthermore, silencing ALDOA expression in ccRCC cell lines decreased their 
proliferative, migratory, and invasive abilities, while ALDOA overexpression increased these 
abilities [42]. 
In addition, the abundance and enzymatic activities of the P- and V-ATPases were found to be 
significantly reduced in our pRCC panel. A possible mechanism by which V-ATPases are thought 
to contribute to cancer cell migration and invasion is to acidify extracellular space to promote the 
activity of acid-dependent proteases that are involved in invasion [19,46,47]. Besides the classical 
role of regulating acidity within a cell, recent studies showed that V-ATPases, as part of the V-
ATPase-Ragulator complex, serve as a dual sensor for energy/nutrient sufficiency and deficiency 
and they can initiate the metabolic switch between catalytic and anabolic pathways [48]. It has been 
further shown and that glycolysis is directly coupled to the V-ATPases by protein-protein 
interactions [49,50].  
The significant reduction of enzymes involved in gluconeogenesis thus has metabolic 
consequences on multiple layers and is a hallmark of all investigated kidney cancers, such as in 
pRCC (this study), ccRCC [29], chRCC [28], and renal oncocytomas [18]. By abandoning this 
endergonic pathway in pRCC the tumor is able to simultaneously reduce other processes involved 
in the generation of ATP. Indeed, pathways involved in fatty acid metabolism, amino acid 
metabolism, as well as OXPHOS and the TCA cycle pathways were significantly down-regulated in 
our pRCC specimen. 
Another frequently observed phenomenon in cancer is the diminished oxidative 
phosphorylation capacity, known already for decades as the “Warburg effect”. The abundance of all 
proteins involved in oxidative phosphorylation and the F0F1ATPase, as well as the corresponding 
enzymatic activities, were significantly reduced in our pRCC panel. This was previously shown for 
chRCC [28] and only for OXPHOS enzymatic activities and the mtDNA content in ccRCC and 
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pRCC [15]. In contrast, the enhanced expression of lactate dehydrogenase A (LDH-A) and lactic 
acid was observed in our study and this has been associated with aggressive and metastatic cancers 
in a variety of tumor types [51–53]. 
By comparing our proteome- with transcriptome data from TCGA [5], the main differentially 
regulated pathway was found to be the respiratory chain, which was the most highly decreased 
pathway on the protein level, but unchanged at the transcript level. A similar discrepancy between 
transcripts and proteins in the regulation of the respiratory chain was previously observed by us in 
benign renal oncocytomas [18] and malignant chRCC [28]. Enzymatic activities of the respiratory 
chain in pRCC and in renal oncocytomas [54] and chRCC [28] matched with protein abundances 
rather than gene expression. The mechanism for this anti-correlation still remains elusive, but might 
be directly correlated to the decreased mtDNA level, or also caused by the interference of miRNAs 
and the stability of transcripts or proteins. This demonstrates the necessity of surveying multiple 
omics profiles.  
The most strikingly increased set of metabolites in pRCC were those involved in glutathione 
metabolism (GSH, GSSG, cysteine-glutathione disulfide, ophthalmic acid). This is similar to those 
previously identified in renal oncocytomas [18,55] and chRCC [28,56]. GSH is an important reactive 
oxygen species (ROS) scavenger [57] and frequently produced by several tumor types to withstand 
unusual levels of oxidative stress [23]. Therefore increased GSH levels in pRCC may be considered 
as the main strategy for the tumor to overcome ROS stress originating from a dysregulated 
respiratory chain.  
By probing the metabolic flux for GSH synthesis, a significant increase of the synthesis rate 
was observed in pRCC derived cell lines over kidney controls when using glutamate as a substrate. 
This is in agreement with another study, which found that glutamine dependence in ccRCC 
suppresses oxidative stress [58]. The inhibition of GSH synthesis by a specific glutaminase (GLS) 
inhibitor and the simultaneous treatment with hydrogen peroxide resulted in a high apoptosis rate 
in ccRCC [58]. Hence, additional administration of antioxidants during (chemotherapeutic) cancer 
treatment have been frequently shown to have no or even pro-tumor effects [59,60]. High GSH 
levels in RCC, which protect the tumor from increased ROS stress, should therefore be 
therapeutically exploited by reducing the antioxidant levels [61], of GSH, and increasing ROS stress 
at the same time to a level where healthy cells can still survive, but tumorous cells are forced into 
apoptosis. 
4. Experimental Procedures 
4.1. Tissue Dissection and Verification of Papillary RCC  
Malignant and non-malignant tissues of 19 nephrectomies performed between 2008 and 2016 
at the Department of Urology, Charité—Universitätsmedizin Berlin, were collected in liquid 
nitrogen immediately after surgery and preserved at −80 °C. The clinical characteristics of the 
tumors are reported in Table 1. From the collected tissue samples, histologic sections were stained 
with hematoxylin and eosin. The diagnosis of pRCC and the corresponding matched tumor-free 
kidney tissue was done according to World Health Organization (WHO) classification criteria. Only 
cases with a clear diagnosis of pRCC were considered for the study. The study was approved by the 
institutional Ethics Committee (no. EA1/134/12, Charité – Universitätsmedizin Berlin) and was 
carried out in accordance with the Declaration of Helsinki. All participants gave informed consent. 
The ethic commission (Ethikausschuss 1 am Campus Charité Mitte, Berlin, Germany) voted on 
14.6.2012 to approve the study with the topic "Nachweis von Biomarkern im Gewebe und in 
Körperflüssigkeiten für die Diagnose und Prognose bei Patienten mit urologischen Tumoren" 
(freely translated: Detection of tissue and body fluid biomarkers for diagnosis and prognosis in 
patients with urological tumors). 
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4.2. Whole Exome Sequencing (WES) 
DNA was isolated from remaining pellets from metabolite extraction using a DNA purification 
kit following the manufacturer's protocol for tissues (QIAmp DNA Mini Kit, Qiagen, Hilden, 
Germany). In brief, samples were digested by proteinase K at 56 °C overnight and RNase A treated 
at 70 °C, before subjecting to exome sequencing. 
The library preparation was performed according to Agilent’s SureSelect protocol 
(SureSelectXT Human All Exon V5, protocol version B4 August 2015), (Agilent, Santa Clara, CA, 
USA) for Illumina paired-end sequencing. In brief, 200 ng of genomic DNA (in 50 μL low Tris-
EDTA(TE)) were sheared for 6 × 60 sec on a Covaris™ S2, (Thermo Scientific, Waltham, MA, USA) 
(duty factor 10%, intensity 5, 200 cycles per burst). 
The fragmented DNA (150–200 bp) was purified using AMPure XP beads and subjected to an 
end-repair reaction. Following another purification step, the DNA was 3’adenylated and 
furthermore purified. Paired-end adaptors were ligated and the afterward purified library was 
amplified with 10 amplification cycles. The amplified library was purified, quantified and 
hybridized to the probe library for exome capture. Captured fragments were purified using 
streptavidin-coated beads and eluted with 30 μl nuclease-free water. Using Herculase-enzyme, the 
enriched libraries were amplified and indexed with barcoded primers followed by cleanup and 
quantification. The resulting libraries were pooled and subjected to Illumina NextSeq4000 (San 
Diego, CA, USA) paired-end sequencing (six libraries/FC; 2 x 150 bp). 
Quantification of the SureSelect captured library: Before sequencing, the samples were re-
quantified with two methods. First, the size and concentration was checked on the Agilent 2100 
Bioanalyzer and in a second step the enrichment efficiency was estimated by qPCR (Applied 
Biosystems, Waltham, MA, USA) using a primer set for an enriched exon (forward : ATCCCGGTTG 
TTCTTCTGTG and reverse: TTCTGGCTCTGCTGTAGGAAG) and a primer set in an intron region 
as a negative control (forward: AGGTTTGCTGAGGAACCTTGA and reverse: 
ACCGAAACATCCTGGCTACAG). In general, the cycle threshold (Ct) -values of target and control 
fragments differed by 6 to 10, thus confirming a very good enrichment of our target regions. 
After diluting the captured libraries to 10 nM, Genome Analyzer single-read flow cells were 
prepared on the supplied Illumina cluster station and 36 bp single-end reads on the Illumina 
Genome Analyzer IIx platform (Illumina, San Diego, California, USA) were generated following the 
manufacturer’s protocol. Images from the instrument were processed using the manufacturer’s 
software to generate FASTQ sequence files. 
4.3. Analysis of mtDNA Mutations 
The FASTQ files were used as input for the MToolBox pipeline [62] in order to extract 
mitochondrial DNA sequences and quantify each variant allele heteroplasmy and related 
confidence interval. The same pipeline allows haplogroup prediction of mtDNA sequences, 
detection of mismatches, insertions and deletions and the functional annotation of the identified 
variants. The in silico prioritization criteria [63] were used to target the mitochondrial DNA variants 
of clinical interest. Thus, variants found in the mitochondrial reference sequences The revised 
Cambridge Reference Sequence (rCRS), the Reconstructed Sapiens Reference Sequence (RSRS) and 
the macro-haplogroup consensus sequence (MHCS), which occurred in non haplogroup-defining 
sites with a nucleotide variability lower than the nucleotide variability cutoff (0.0026) and a disease 
score above the disease score threshold of 0.43 for non-synonymous coding for proteins, 0.35 for 
tRNA, and 0.60, for rRNA variants were prioritized. 
4.4. Sample Preparation for Proteomics 
About 10 mg frozen tissue per sample was homogenized under denaturing conditions with a 
FastPrep instrument (three times for 60 s, 6.5 m × s-1) in a buffer containing 4% sodium dodecyl 
sulfate (SDS), 0.1 M dithiothreitol (DTT), 0.1 M Tris pH 7.8, followed by sonication for 5 min, 
boiled at 95 °C for 5 min and precipitated with acetone at −20 °C overnight. Lyophilized proteins 
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were dissolved in 6 M guanidinium chloride, 10 mM tris(2-carboxyethyl)phosphine, 40 mM 
chloroacetamide, and 100 mM Tris pH 8.5. Samples were boiled for 5 min at 95 °C and 
sonicated for 15 min in a water sonicator. The lysates were diluted 1:10 with nine times volume 
of 10% acetonitrile and 25 mM Tris, 8.5 pH, followed by trypsin digestion (1:100) at 37 °C 
overnight. Subsequent, the peptides were purified with C18 columns. For whole proteome 
profiling, 90 μg of each sample was fractionated by strong cation exchange (SCX) chromatography. 
Five μg of each SCX fraction was used for proteome profiling. 
4.5. LC-MS Instrument Settings for Shotgun Proteome Profiling and Data Analysis 
Liquid chromatography–mass spectrometry (LC-MS/MS) was carried out by nanoflow reverse 
phase liquid chromatography (Dionex Ultimate 3000, Thermo Scientific) coupled online to a Q-
Exactive HF Orbitrap mass spectrometer (Thermo Scientific). Briefly, the LC separation was 
performed using a PicoFrit analytical column (75 μm ID × 55 cm long, 15 μm Tip ID (New 
Objectives, Woburn, MA, USA) in-house packed with 3-μm C18 resin (Reprosil-AQ Pur, Dr. 
Maisch, Ammerbuch-Entringen, Germany). Peptides were eluted using a gradient from 3.8 to 40% 
solvent B (79.9% acetonitrile, 20% water, 0.1% formic acid) in solvent A (0.1 % formic acid in water) 
over 120 min at 266 nL per minute flow rate. Nanoelectrospray was generated by applying 3.5 kV. 
A cycle of one full Fourier transformation scan mass spectrum (300−1750 m/z, resolution of 60,000 at 
m/z 200, AGC target 1e6) was followed by 16 data-dependent MS/MS scans (resolution of 30,000, 
AGC target 5e5) with a normalized collision energy of 27 eV. In order to avoid repeated sequencing 
of the same peptides, a dynamic exclusion window of 30 sec was used. In addition, only peptide 
charge states between two to eight were sequenced. 
Raw MS data were processed with MaxQuant software v1.6.0.1 (MPI of Biochemistry, Munich, 
Germany) [64] and searched against the human proteome database UniProtKB with 70,941 entries, 
released in 01/2017. Parameters of MaxQuant database searching were: A false discovery rate (FDR) 
of 0.01 for proteins and peptides, a minimum peptide length of 7 amino acids, a mass tolerance of 
4.5 ppm for precursor and 20 ppm for fragment ions were required. A maximum of two missed 
cleavages was allowed for the tryptic digest. Cysteine carbamidomethylation was set as fixed 
modification, while N-terminal acetylation and methionine oxidation were set as variable 
modifications. MaxQuant processed output files can be found in Table S1, showing peptide and 
protein identification, accession numbers, % sequence coverage of the protein, q-values, and label-
free quantification (LFQ) intensities. Contaminants, as well as proteins identified by site 
modification and proteins derived from the reversed part of the decoy database, were strictly 
excluded from further analysis. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the Pride partner repository [65] with the dataset identifier 
PXD013523. 
4.6. Metabolite Extraction and Profiling by Targeted LC-MS 
About 30 mg of 16 pRCC and healthy kidney tissues, shock-frozen in liquid nitrogen, was used 
for metabolite profiling. Metabolite extraction and tandem LC-MS measurements were done as we 
have previously reported [18,66]. In brief, methyl-tert-butyl ester (MTBE), methanol, ammonium 
acetate, and water were used for metabolite extraction. Subsequent separation was performed on an 
LC instrument (1290 series UHPLC; Agilent, Santa Clara, CA, USA), online coupled to a triple 
quadrupole hybrid ion trap mass spectrometer QTrap 6500 (Sciex, Foster City, CA, USA), as 
reported previously [67]. Transition settings for multiple reaction monitoring (MRM) are provided 
in Table S9. The mass spectrometry data have been deposited in the publically available repository 
PeptideAtlas and can be obtained via http://www.peptideatlas.org/PASS/PASS01368.  
The metabolite identification was based on three levels: (i) the correct retention time, (ii) up to 
three MRM’s and (iii) a matching MRM ion ratio of tuned pure metabolites as a reference [67]. 
Relative quantification was performed using MultiQuant software v.2.1.1 (Sciex). The integration 
setting was a peak splitting factor of 0 and all peaks were reviewed manually. Only the average 
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peak area of the first transition was used for calculations. Normalization was done according to 
used amounts of tissues and subsequently by internal standards, as indicated in Table S8.  
4.7. Cell Culture Conditions for Glutathione and Proline de novo Synthesis  
The two pRCC-derived cell lines Caki-2 (ATCC HTB-47, reclassified from ccRCC [68]) and 
ACHN (ATCC CRL-1611) and the human kidney (HK-2, cortex/proximal tubule, ATCC CRL-2190) 
cell line were cultivated in Dulbecco’s modified Eagle medium (DMEM, Life Technologies, New 
York, NY, USA) containing 4.5 g/L glucose, supplemented with 10% fetal bovine serum (FBS, 
Silantes, Munich, Germany) and 1% penicillin–streptomycin–neomycin (Invitrogen, Carlsbad, CA, 
USA) at 37 °C in a humidified atmosphere of 5% CO2.  
To determine the source for GSH de novo synthesis and potential differences between the 
pRCC cell lines Caki-2 and ACHN versus HK-2 kidney controls, two isotope tracing experiments 
were performed. The first experiment employed 13C6 labeled glucose, the second 13C515N glutamic 
acid as probe, a scheme of GSH synthesis is outlined in figure 7. In addition, proline de novo 
synthesis was monitored simultaneously within the experimental setting of glutamate as a tracer 
(Figure 6J). 
GSH labeling dynamics were probed by sampling at time points 0, 12, and 24 hours, for proline 
0 and 12 hours were taken in 6-well plate triplicates for all three cell lines. The cells were rinsed 
twice with PBS and replenished at time point 0 by either a glucose-free DMEM medium with the 
addition of 5 mM 13C6 glucose (Cambridge Isotope Laboratories Inc., Tewksbury, MA, USA), 10% 
dialyzed FBS and 1% penicillin/streptomycin, or by HBSS solution supplemented with 2 mM 
13C515N-glutamic acid (Cambridge Isotope Laboratories), 5 mM glucose, 0.4 mM glycine, 10% 
dialyzed FBS and 1% penicillin/streptomycin. Before metabolite extraction, cells were washed twice 
by PBS, ice-cold methanol (−80 °C) was added and the cells were scraped from the plate and 
metabolites were extracted as described for tissues. The MRM method was extended to also include 
isotope-transitions for metabolites originating from labeled glucose and glutamate (Table S9). As 
GSSG can be made of either one or two labeled GSH molecules, both versions were measured (13C6 
glucose: M+3 and M+6; 13C515N-glutamic acid: M+5 and M+10).  
4.8. Experimental Design, Statistical Rationale, and Pathway Analyses 
Seven pRCC type I, seven pRCC type II, and five pRCC type II metastatic cancer samples were 
compared with adjacent matched normal kidney tissues. For quantitative proteome profiling, 
nanoscale liquid chromatography coupled to high-resolution mass spectrometry (nano-LC-MS/MS) 
was used to quantify the abundance of dysregulated proteins. For quantitative metabolome 
profiling, a UHPLC coupled to a QTrap instrument (Sciex) was used for the targeted approach 
(multiple reaction monitoring, MRM) to identify and quantify the abundance of dysregulated 
metabolites. 
For proteome and metabolome data sets, a two-sample t-test was performed. Multiple test 
correction was done by Benjamini-Hochberg with an FDR of 0.05 by using Perseus v1.6.0.2 [69]. 
Significantly regulated proteins and metabolites were marked by a plus sign in the corresponding 
Tables S2 and S9. The Pearson correlation was based on “valid values” for each pRCC type in 
Perseus. 
For comprehensive proteome data analyses, gene set enrichment analysis GSEA, v3.0 (Broad 
institute, San Diego, USA) [70] was applied in order to see, if a priori defined sets of proteins show 
statistically significant, concordant differences between pRCC and kidney tissues. Only proteins 
with valid values in at least seven of ten samples in at least one group with replacing missing 
values from the normal distribution for the other group were used (Table S2). GSEA default settings 
were applied, except that the minimum size exclusion was set to 5 and KEGG v5.2 was used as a 
gene set database. The cut-off for significantly regulated pathways was set to a p-value ≤ 0.01 and 
FDR ≤ 0.10. 
For protein-protein interaction (PPI) network analyses, the software tool String v.10.5 (CPR, 
EMBL, SIB, KU, and UZH) has been used to visualize networks of significantly up- or down-
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regulated proteins with a confidence level of 0.7 [71]. High blood contamination was identified in 
the following five samples: pRCC type I kidney 7 and case 5; pRCC type II case 7; pRCC type IIM 
kidney 3 and case 2; which were then excluded from further proteome and metabolome analysis. 
These exclusions were based on the individual GSEA pathway and the String PPI network results, 
where the pathways “coagulation cascade” or “blood particles” were significantly enriched.  
5. Conclusion  
Key metabolic reprogramming processes, such those for gluconeogenesis, the respiratory 
chain, and glutathione metabolism are not only the main molecular characteristics for papillary 
RCC, but rather seem to be a general feature for other kidney tumors as well. Specifically, the 
reinforcement of glutathione metabolism, reflecting the increased burden of oxidative stress, and 
abandoning endergonic processes may hold key therapeutic implications as a future treatment 
option. 
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